English
Zoom-Zoom+Black contrastBlue contrastWhite contrast

How to use the speech recognition tool?

NCT02064569

An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene

An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene.

Type: Interventional



Status of the trial: Completed

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2016-10-13
  • Closing Date: 2021-12-12

Criteria

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Neuro-Ophthalmology Rare Diseases (WG2)

Subscribe to our mailing list

* indicates required

This ERN is supported by: